Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 24;11:5962. doi: 10.1038/s41467-020-19780-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a, b Ketamine decreased MAGL expression (unpaired two-tailed t test, t(6) = 2.732, P = 0.0341) but increased PRDM5 expression in the cultured SPNs (unpaired two-tailed t test, t(6) = 2.527, P = 0.0449). Ketamine did not affect DAGL expression (unpaired two-tailed t test, t(6) = 0.1882, P = 0.8569). c Ketamine increased the 2-AG level in the cultured SPNs (unpaired two-tailed t test, t(6) = 2.951, P = 0.0256). d Representative immunofluorescent images of PRDM5 (green) and DAPI (blue). e Ketamine increased PRDM5 expression (unpaired two-tailed t test, t(14) = 2.89, P = 0.0119). f, g Representative immunofluorescent images of MAGL (red) and DAPI (blue). Ketamine decreased MAGL expression (unpaired two-tailed t test, t(14) = 7.16, P < 0.0001). Compared to SAL group, *P < 0.05, **P < 0.01. h, i LV-shPrdm5 restored MAGL expression downregulated by ketamine (one-way ANOVA, followed by Dunnett’s multiple comparisons test: PRDM5 F(3,8) = 95.58, P < 0.0001; VEH + KET vs. VEH + SAL, P = 0.0071, VEH + KET vs. LV-shPrdm5 + KET, P < 0.0001; MAGL F(3,8) = 20.09, P = 0.0004; VEH + KET vs. VEH + SAL, P = 0.0299, VEH + KET vs. LV-shPrdm5 + KET, P = 0.0008). j LV-shPrdm5 reversed ketamine-elevated 2-AG level (one-way ANOVA, followed by Dunnett’s multiple comparisons test, F(3,12) = 5.395, P = 0.0139; VEH + KET vs. VEH + SAL, P = 0.0386, VEH + KET vs. LV-shPrdm5 + KET, P = 0.0364). Compared to SCR + SAL group, *P < 0.05; compared to SCR + KET group, ^#P < 0.05, ^###P < 0.001. Data are shown as mean ± SEM. SAL saline, KET ketamine. Source data provided as a Source Data file.